SCHEMBL6462166

SCHEMBL6462166

COCCNCc1cccc(-c2sc(C(C)(C)c3c(Cl)cc(-n4ncc(=O)[nH]c4=O)cc3Cl)nc2-c2ccccc2Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 5/20 0.38
ABCB11 O95342 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
PIK3CD O00329 1/20 0.33
DGAT2 Q96PD7 1/20 0.33
PDCD1 Q15116 2/20 0.33
CD274 Q9NZQ7 2/20 0.33
THRB P10828 5/20 0.32
PRKCB P05771 1/20 0.31
PRKCA P17252 1/20 0.31
PRKCH P24723 1/20 0.31
PRKCE Q02156 1/20 0.31
PRKCQ Q04759 1/20 0.31
PRKCD Q05655 1/20 0.31
AVPR1B P47901 1/20 0.31
CASR P41180 1/20 0.31
P4HTM Q9NXG6 1/20 0.31
TLR7 Q9NYK1 1/20 0.30
THRA P10827 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6459797 0.86 P2RX7 (0.39) P2RX7ABCB11THRBTHRA
SCHEMBL6462226 0.83 P2RX7 (0.46) P2RX7ABCB11DGAT2THRB
SCHEMBL6460370 0.83 P2RX7 (0.34) P2RX7ABCB11THRB
SCHEMBL6460365 0.83 P2RX7 (0.34) P2RX7ABCB11THRB
SCHEMBL6461284 0.83 P2RX7 (0.35) P2RX7ABCB11THRBTHRA
SCHEMBL7135587 0.81 P2RX7 (0.38) P2RX7ABCB11THRBTHRA
SCHEMBL6462754 0.78 P2RX7 (0.41) P2RX7ABCB11THRBTHRA
SCHEMBL6459898 0.77 THRB (0.39) P2RX7ABCB11THRBTHRA
SCHEMBL6461628 0.76 ADORA2A (0.38) P2RX7ABCB11PIK3CDTHRBTHRA
SCHEMBL7705288 0.76 P2RX7 (0.37) P2RX7ABCB11THRBTHRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894046-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-17 US disclosed
EP-1114046-B1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2003-04-23 EP disclosed
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives JANSSEN CILAG S.A. (FR) 2002-01-24 US disclosed
EP-1114046-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-07-11 EP disclosed
WO-2000017195-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives ALOX5, IL5, IL6ST P2RX7 880/4885ABCB11 2670/4885HSP90AA1 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.